Clinical trial · no report yet · Phase 1/Phase 2
EPCORE™ NHL-2
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
- NCT04663347 ↗
- Active, not recruiting
- Genmab
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Podcasts | 1 | |
| X threads | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Diffuse Large B-Cell Lymphoma; Follicular Lymphoma
- Interventions
- rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; rituximab and lenalidomide; rituximab and bendamustine; rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin; gemcitabine and oxaliplatin; Epcoritamab; rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone; Lenalidomide; rituximab, ifosfamide, carboplatin, and etoposide phosphate; Epcoritamab; Epcoritamab; Epcoritamab; Epcoritamab; Epcoritamab; Epcoritamab; Epcoritamab; Rituximab and Lenalidomide; Epcoritamab
- Arms
- Arm 1 - Epcoritamab + R-CHOP · Experimental
- Arm 2 - Epcoritamab + R2 · Experimental
- Arm 3 - Epcoritamab + BR · Experimental
- Arm 4 - Epcoritamab + R-DHAX/C · Experimental
- Arm 5 - Epcoritamab + GemOx · Experimental
- Arm 6 - Epcoritamab + R2 · Experimental
- Arm 7 - Epcoritamab maintenance · Experimental
- Arm 8 - Epcoritamab + R mini-CHOP · Experimental
- Arm 9 - Epcoritamab + Lenalidomide · Experimental
- Arm 10 - Epcoritamab + R-ICE · Experimental
- Enrollment
- 543
- Primary outcomes
- Part 1: Number of Participants With Dose limiting Toxicities (DLTs)
- Part 1 and Part 2 (Arms 1-5, 7 and 10): Number of Participants With Adverse Events (AEs)
- Part 2 (Except Arm 7): Overall Response Rate (ORR)
- Sponsor
- Genmab with AbbVie
- Start
- Nov 3, 2020
- Primary completion
- Sep 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04663347 · updated Oct 6, 2026
Publications
linked from the registry- Falchi L, Vermaat JSP, Brody JD, Leslie L, Offner F, Christensen JH, Nijland M, Belada D, Wahlin BE, Drott K, Gomez Prieto P, Kopeckova K, Garcia-Sancho AM, Mei JP, Altintas I, Risum M, Reilly A, Zou J, Abrisqueta P. Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial. Lancet Haematol. 2026 Sep;13(9):e614-e625. doi: 10.1016/S2352-3026(26)00198-5. PubMed 42660129
- Falchi L, Offner F, de Vos S, Brody JD, Morillo D, Linton K, Snauwaert S, Roost Clausen M, Karimi YH, Thieblemont C, Vitolo U, Leslie LA, Narkhede MS, Cordoba R, Oki T, Wielgos-Bonvallet M, Khoshdeli M, Hao Y, Archer K, Risum M, Belada D. Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial. Blood. 2026 Aug 11:blood.2026033839. doi: 10.1182/blood.2026033839. Online ahead of print. PubMed 42622258
- Abrisqueta P, Karimi YH, Morillo D, Cordoba R, Phillips T, De Vos S, Nijland M, Offner F, Andersson PO, Brody J, Cheah CY, Prieto PG, Hellstrom M, Jorgensen JM, Lewis D, Linton KM, Musuraca G, Wang L, Marek J, Osei-Bonsu K, Risum M, Falchi L. Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial. Haematologica. 2026 Oct 1;111(10):3346-3357. doi: 10.3324/haematol.2025.300086. Epub 2026 Mar 5. PubMed 41784015
- Falchi L, Sureda A, Leppa S, Vermaat JSP, Nijland M, Christensen JH, de Vos S, Holte H, Merryman RW, Lugtenburg PJ, Abrisqueta P, Linton KM, Sunkersett G, Hoehn D, Rana A, Abbas A, Marek J, Hao Y, Steele AJ, Morehouse C, Hutchings M, Belada D. Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma. Blood. 2025 Nov 27;146(22):2629-2640. doi: 10.1182/blood.2025029909. PubMed 40920572
- Brody JD, Jorgensen J, Belada D, Costello R, Trneny M, Vitolo U, Lewis DJ, Karimi YH, Sureda A, Andre M, Wahlin BE, Lugtenburg PJ, Jiang T, Karagoz K, Steele AJ, Abbas A, Wang L, Risum M, Cordoba R. Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial. Blood. 2025 Apr 10;145(15):1621-1631. doi: 10.1182/blood.2024026830. PubMed 39792928